Download or read book Impact of Gene Expression Profiling Tests on Breast Cancer Outcomes written by Luigi Marchionni and published by DIANE Publishing. This book was released on 2009-05 with total page 230 pages. Available in PDF, EPUB and Kindle. Book excerpt: Assesses the evidence that three marketed gene expression-based assays improve prognostic accuracy, treatment choice, and health outcomes in women diagnosed with early stage breast cancer. Three gene expression assays were evaluated; Oncotype DX¿, MammaPrint® and the Breast Cancer Profiling (BCP or H/I ratio) test, and for gene expression signatures underlying the assays. They sought evidence on: analytic performance of tests; clinical validity; clinical utility; harms; and impact on clinical decision making and health care costs. Conclusions: Oncotype DX is furthest along the validation pathway, with retrospective evidence that it predicts distant spread and chemotherapy benefit to a clinically relevant extent over standard predictors. Illus.

Download or read book Impact of Gene Expression Profiling Tests on Breast Cancer Outcomes written by Luigi Marchionni (M.D.) and published by . This book was released on 2008-01-01 with total page 105 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Impact of Gene Expression Profiling Tests on Breast Cancer Outcomes written by and published by . This book was released on 2008 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Adjuvant Therapy for Breast Cancer written by Monica Castiglione and published by Springer Science & Business Media. This book was released on 2009-07-11 with total page 483 pages. Available in PDF, EPUB and Kindle. Book excerpt: Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable.

Download or read book The Economic and Clinical Outcomes and Policy Implications of Gene Expression Profiling in Breast Cancer Care written by Nina Oestreicher and published by . This book was released on 2004 with total page 164 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book High Risk Cutaneous Squamous Cell Carcinoma written by Chrysalyne D. Schmults and published by Springer. This book was released on 2016-04-29 with total page 261 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is a cutting-edge resource that provides clinicians with the up-to-date practical knowledge required in order to manage SCC patients optimally. It summarizes newly available information relating to the definition of high-risk SCC, its pathophysiologic underpinnings, and its management. New prognostic information and staging systems are summarized that enable high-risk tumors to be defined more precisely than ever before. Many helpful tips are provided on the practical management of challenging cases, including multiple tumors/field cancerization, high-risk tumors, nodal metastases, and unresectable disease. The authors are all acknowledged experts in the emerging field of high-risk and advanced SCC.​

Download or read book The Application of Gene Expression Profiling to Clinical Breast Cancer Research written by Sherene Loi and published by LAP Lambert Academic Publishing. This book was released on 2009 with total page 280 pages. Available in PDF, EPUB and Kindle. Book excerpt: The book has three main results parts. Chapter 3 illustrates the first independent validation study of a 70-gene signature developed from gene expression profiling for use in breast cancer prognosis and demonstration of its ability to add independent prognostic information to the clinical prognostic factors currently used. The successful validation of this study preceded the design and implementation of a world-wide randomized clinical trial evaluating the gene signature's clinical utility. This trial has commenced and is currently recruiting in Europe. Chapter 4 describes the finding that proliferation-related genes can predict clinical outcome consistently in breast cancer and many gene signatures developed for predicting breast cancer prognosis derive a significant proportion of their prognostic power from these genes. Finally, chapter 5 describes the use of proliferation-related genes to define two distinct prognostic molecular subgroups within estrogen receptor positive breast cancers.

Download or read book Gene Expression Profiling of the Breast Tumour Microenvironment written by Grzegorz Finak and published by . This book was released on 2008 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: "Breast cancer is a very heterogeneous disease. This heterogeneity can be observed at many levels, including gene expression, chromosomal aberrations, and disease pathology. A clear understanding of these differences is important since they impact upon treatment efficacy and clinical outcome. Recent studies have demonstrated that the tumour microenvironment also plays a critical role in cancer initiation and progression. Genomic technologies have been used to gain a better understanding of the impact of gene expression heterogeneity on breast cancer, and have identified gene expression signatures associated with clinical outcome, histopathological breast cancer subtypes, and a variety of cancer-related pathways and processes. However, little work has been done in this context to examine the role of the tumour microenvironment in determining breast cancer outcome, or in defining breast cancer heterogeneity. Additionally, little is known about gene expression in histologically normal tissue adjacent to breast tumour, if this is influenced by the tumour, and how this compares with non-tumour-bearing breast tissue. By applying laser--capture microdissection and gene expression profiling to clinical breast cancer specimens the research presented in this thesis addresses these questions. We have generated gene expression profiles of morphologically normal epithelial and stromal tissue, isolated using laser capture microdissection, from patients with breast cancer or undergoing breast reduction mammoplasty. We determined that morphologically normal epithelium and stroma exhibited distinct expression profiles, but molecular signatures that distinguished breast reduction tissue from tumour-adjacent normal tissue were absent. Stroma isolated from morphologically normal ducts adjacent to tumour tissue contained two distinct expression profiles that correlated with stromal cellularity, and shared similarities with soft tissue tumors with favourable outcome. Adjacent normal epithelium and stroma from breast cancer patients showed no significant association between expression profiles and standard clinical characteristics, but did cluster ER/PR/HER2-negative breast cancers with basal-like subtype expression profiles with poor prognosis. Our data reveal that morphologically normal tissue adjacent to breast carcinomas has not undergone significant gene expression changes when compared to breast reduction tissue, and provide an important gene expression data set for comparative studies of tumour expression profiles. We compared gene expression profiles of tumour stroma from primary breast tumors and derived signatures strongly associated with clinical outcome. We present a new stroma-derived prognostic predictor (SDPP) that stratifies disease outcome independently of standard clinical prognostic factors and published expression-based predictors. The SDPP predicts outcome in several published whole tumour--derived expression data sets, identifies poor-outcome individuals from multiple clinical subtypes, including lymph node--negative tumors, and shows increased accuracy with respect to previously published predictors, especially for HER2-positive tumors. Prognostic power increases substantially when the predictor is combined with existing outcome predictors. Genes represented in the SDPP reveal the strong prognostic capacity of differential immune responses as well as angiogenic and hypoxic responses, highlighting the importance of stromal biology in tumour progression. We show that gene expression in the breast tumour microenvironment is highly heterogeneous, identifying at least six different classes of tumour stroma with distinct expression patterns and distinct biological processes. Two of these classes recapitulate the processes identified in the stroma-derived prognostic predictor, while the others are new classes of stroma associated with distinct clinical outcomes. One of these is associated with matrix remodelling and is strongly associated with the basal molecular subtype of breast cancer. The remainder are independent of the previously published molecular subtypes of breast cancer. Additionally, based on independent data from over 800 tumors, the combinations of stroma classes and breast cancer subtypes identify new subgroups of breast tumors that show better discrimination between good and poor outcome individuals than the molecular breast cancer subtypes or the stroma classes alone, suggesting a novel classification scheme for breast cancer. This research demonstrates an important role for the tumour microenvironment in defining breast cancer heterogeneity, with a consequent impact upon clinical outcome. Novel therapies could be targeted at the processes that define the stroma classes suggesting new avenues for individualized treatment."--

Download or read book A Comparison of Gene Expression Profiling Tests for Breast Cancer written by Pam Smartt and published by . This book was released on 2010 with total page 102 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Targeted Therapies for Lung Cancer written by Ravi Salgia and published by Springer. This book was released on 2019-06-26 with total page 238 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient’s genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.

Download or read book Economic Evaluation of Potential Applications of Gene Expression Profiling in Clinical Oncology written by Malek Hannouf and published by . This book was released on 2014 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: Histopathological analysis of tumor is currently the main tool used to guide cancer management. Gene expression profiling may provide additional valuable information for both classification and prognostication of individual tumors. A number of gene expression profiling assays have been developed recently to inform therapy decisions in women with early stage breast cancer and help identify the primary tumor site in patients with metastatic cancer of unknown primary. The impact of these assays on health and economic outcomes, if introduced into general practice, has not been determined. I aimed to conduct an economic evaluation of regulatory-approved gene expression profiling assays for breast cancer and cancer of unknown primary for the purpose of determining whether these technologies represent value for money from the perspective of the Canadian health care system. I developed decision-analytic models to project the lifetime clinical and economic consequences of early stage breast cancer and metastatic cancer of unknown primary. I used Manitoba Cancer Registry and Manitoba administrative health databases to model current real-world Canadian clinical practices. I applied available data about gene expression profiling assays from secondary sources on these models to predict the impact of these assays on current clinical and economic outcomes. In the base case, gene expression profiling assays in early stage breast cancer and cancer of unknown primary resulted in incremental cost effectiveness ratios of less than $100,000 per quality-adjusted life-year gained. These results were most sensitive to the uncertainty associated with the accuracy of the assay, patient-physician response to gene expression profiling information and patient survival. The potential application of these gene expression profiling assays in clinical oncology appears to be cost-effective in the Canadian healthcare system. Field evaluation of these assays to establish their impact on cancer management and patient survival may have a large societal impact and should be initiated in Canada to ensure their clinical utility and cost-effectiveness. The use of Canadian provincial administrative population data in decision modeling is useful to quantify uncertainty about gene expression profiling assays and guide the use of novel funding models such as conditional funding alongside a field evaluation.

Download or read book Gene Expression Profiling Tests for Breast Cancer written by Andrea Smith (Of Canadian Agency for Drugs and Technologies in Health) and published by . This book was released on 2019 with total page 24 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Advancing the Science of Cancer in Latinos written by Amelie G. Ramirez and published by Springer Nature. This book was released on 2019-11-21 with total page 320 pages. Available in PDF, EPUB and Kindle. Book excerpt: This open access book gives an overview of the sessions, panel discussions, and outcomes of the Advancing the Science of Cancer in Latinos conference, held in February 2018 in San Antonio, Texas, USA, and hosted by the Mays Cancer Center and the Institute for Health Promotion Research at UT Health San Antonio. Latinos – the largest, youngest, and fastest-growing minority group in the United States – are expected to face a 142% rise in cancer cases in coming years. Although there has been substantial advancement in cancer prevention, screening, diagnosis, and treatment over the past few decades, addressing Latino cancer health disparities has not nearly kept pace with progress. The diverse and dynamic group of speakers and panelists brought together at the Advancing the Science of Cancer in Latinos conference provided in-depth insights as well as progress and actionable goals for Latino-focused basic science research, clinical best practices, community interventions, and what can be done by way of prevention, screening, diagnosis, and treatment of cancer in Latinos. These insights have been translated into the chapters included in this compendium; the chapters summarize the presentations and include current knowledge in the specific topic areas, identified gaps, and top priority areas for future cancer research in Latinos. Topics included among the chapters: Colorectal cancer disparities in Latinos: Genes vs. Environment Breast cancer risk and mortality in women of Latin American origin Differential cancer risk in Latinos: The role of diet Overcoming barriers for Latinos on cancer clinical trials Es tiempo: Engaging Latinas in cervical cancer research Emerging policies in U.S. health care Advancing the Science of Cancer in Latinos proves to be an indispensable resource offering key insights into actionable targets for basic science research, suggestions for clinical best practices and community interventions, and novel strategies and advocacy opportunities to reduce health disparities in Latino communities. It will find an engaged audience among researchers, academics, physicians and other healthcare professionals, patient advocates, students, and others with an interest in the broad field of Latino cancer.

Download or read book Mammography and Beyond written by National Research Council and published by National Academies Press. This book was released on 2001-06-04 with total page 34 pages. Available in PDF, EPUB and Kindle. Book excerpt: X-ray mammography screening is the current mainstay for early breast cancer detection. It has been proven to detect breast cancer at an earlier stage and to reduce the number of women dying from the disease. However, it has a number of limitations. These current limitations in early breast cancer detection technology are driving a surge of new technological developments, from modifications of x-ray mammography such as computer programs that can indicate suspicious areas, to newer methods of detection such as magnetic resonance imaging (MRI) or biochemical tests on breast fluids. To explore the merits and drawbacks of these new breast cancer detection techniques, the Institute of Medicine of the National Academy of Sciences convened a committee of experts. During its year of operation, the committee examined the peer-reviewed literature, consulted with other experts in the field, and held two public workshops. In addition to identifying promising new technologies for early detection, the committee explored potential barriers that might prevent the development of new detection methods and their common usage. Such barriers could include lack of funding from agencies that support research and lack of investment in the commercial sector; complicated, inconsistent, or unpredictable federal regulations; inadequate insurance reimbursement; and limited access to or unacceptability of breast cancer detection technology for women and their doctors. Based on the findings of their study, the committee prepared a report entitled Mammography and Beyond: Developing Technology for Early Detection of Breast Cancer, which was published in the spring of 2001. This is a non-technical summary of that report.

Download or read book Molecular Pathology of Breast Cancer written by Sunil Badve and published by Springer. This book was released on 2016-11-26 with total page 427 pages. Available in PDF, EPUB and Kindle. Book excerpt: The complex landscape of breast cancer requires distinct strategies for the management of various molecular subtypes of this disease. Rapid advances in the field of molecular biology have been bewildering for those involved in its study and management. “Molecular Pathology of Breast Cancer” aims to close this knowledge gap by discussing comprehensively the evolution, biological basis and clinical applications with a focus on the “what, when, and how” of the most significant molecular markers known to date. These markers are evaluated in the context of genomic, transcriptomic and proteomic profiles, which is integral to the practice of precision medicine. The application of next generation sequencing (NGS) has provided new insights in the regulation of genomic and transcriptomic structure and function. Alterations in DNA such as mutations and single nucleotide polymorphisms (SNPs) have been correlated with outcomes and provide for novel therapeutic approaches. These NGS analyses have also revealed the extensive contributions of epigenetic mechanisms such as histone modifications, non-coding RNA and alternative splicing. All of these changes together contribute to alterations in proteome. Newer assays that allow greater stability and analytical consistency are emerging. These alterations in tumor profiles can be also now detected by imaging techniques. The heterogeneity of both tumor and tumor microenvironment, an inevitable reality, is discussed in detail with particular focus on cancer stem cells and immune signaling. A chapter is dedicated to the emerging technology of “liquid biopsy”, which opens a novel approach for “continuous” monitoring of cancer that might be superior to conventional diagnostics, “Molecular Pathology of Breast Cancer” provides a quick and easy, not to mention essential, tour for clinicians, pathologists and scientists who are seeking to understand the integration of molecular biology into the diagnosis, prognosis and management of breast cancer.

Download or read book Adverse Effects of Cancer Chemotherapy Anything New to Improve Tolerance and Reduce Sequelae written by Kulmira Nurgali and published by Frontiers Media SA. This book was released on 2018-06-12 with total page 245 pages. Available in PDF, EPUB and Kindle. Book excerpt: Advances in anti-cancer chemotherapy over recent years have led to improved efficacy in curing or controlling many cancers. Some chemotherapy-related side-effects are well recognized and include: nausea, vomiting, bone marrow suppression, peripheral neuropathy, cardiac and skeletal muscle dysfunction and renal impairment. However, it is becoming clearer that some chemotherapy-related adverse effects may persist even in long term cancer survivors. Problems such as cognitive, cardiovascular and gastrointestinal dysfunction, and neuropathy may lead to substantial long term morbidity. Despite improvements in treatments to counteract acute chemotherapy-induced adverse effects, they are often incompletely effective. Furthermore, counter-measures for some acute side-effects and many potential longer term sequelae of anti-cancer chemotherapy have not been developed. Thus, new insights into prevalence and mechanisms of cancer chemotherapy-related side effects are needed and new approaches to improving tolerance and reduce sequelae of cancer chemotherapy are urgently needed. The present Research Topic focuses on adverse effects and sequelae of chemotherapy and strategies to counteract them.

Download or read book Applying Machine Learning to Breast Cancer Gene Expression Data to Predict Survival Likelihood written by Pegah Tavangar and published by . This book was released on 2020 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: Analyzing the expression level of thousands of genes will provide additional information beneficial in improving cancer therapy or synthesizing a new drug. In this project, the expression of 48807 genes from primary human breast tumors cells was analyzed. Humans cannot make sense of such a large volume of gene expression data from each person. Therefore, we used Machine Learning as an automated system that can learn from the data and be able to predict results from the data. This project presents the use of Machine Learning to predict the likelihood of survival in breast cancer patients using gene expression profiling. Machine Learning techniques, such as Logistic Regression, Support Vector Machines, Random Forest, and different Feature Selection techniques were used to find essential genes that lead to breast cancer or help a patient to live longer. This project describes the evaluation of different Machine Learning algorithms to classify breast cancer tumors into two groups of high and low survival.